Human medicines European public assessment report (EPAR): Adakveo, crizanlizumab, Anemia, Sickle Cell, Date of authorisation: 28/10/2020, Revision: 4, Status: Authorised
Adakveo is a medicine for preventing painful crises in patients with sickle cell disease aged 16 years and older.
Sickle cell disease is a genetic condition in which the red blood cells become rigid and sticky and change from being disc-shaped to being crescent-shaped (like a sickle). They can block the flow of blood in blood vessels, causing painful crises that affect the chest, abdomen and other parts of the body.
Adakveo can be used as an add-on treatment with hydroxycarbamide (also known as hydroxyurea) or on its own in patients for whom hydroxycarbamide does not work well enough or causes too many side effects. Adakveo contains the active substance crizanlizumab.
Sickle cell disease is rare, and Adakveo was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 9 August 2012.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
